科兴四价流感疫苗扩龄获批 覆盖6月龄及以上人群

Core Viewpoint - The approval of the quadrivalent influenza virus split vaccine by Beijing Kexing Biological Products Co., Ltd. for an expanded age range enhances the accessibility of high-quality influenza vaccines in China [1] Group 1 - The National Medical Products Administration (NMPA) approved the age expansion application for the quadrivalent influenza vaccine, now applicable to individuals aged 6 months and older [1] - The vaccine's new approval provides a unified dosage form for influenza prevention, offering a new choice for high-quality vaccination [1] - This development is expected to further improve the accessibility of influenza vaccination in China [1]